Maze Therapeutics, Inc. (NASDAQ:MAZE) Receives Average Recommendation of “Buy” from Analysts

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) have been assigned an average rating of “Buy” from the eleven research firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, eight have issued a buy rating and two have given a strong buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $66.00.

Several brokerages have weighed in on MAZE. Guggenheim increased their price target on Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. JPMorgan Chase & Co. increased their price target on Maze Therapeutics from $52.00 to $58.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 31st. Wall Street Zen raised Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Wedbush increased their price target on Maze Therapeutics from $43.00 to $58.00 and gave the stock an “outperform” rating in a research report on Monday, March 16th. Finally, Mizuho raised Maze Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 11th.

Maze Therapeutics Stock Performance

MAZE opened at $25.57 on Tuesday. Maze Therapeutics has a 12-month low of $9.83 and a 12-month high of $53.65. The company has a current ratio of 17.88, a quick ratio of 17.88 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $1.42 billion, a PE ratio of -10.11 and a beta of 2.27. The firm has a 50 day moving average of $25.68 and a two-hundred day moving average of $36.36.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The business had revenue of $20.00 million for the quarter. On average, analysts anticipate that Maze Therapeutics will post -2.76 EPS for the current year.

Insider Buying and Selling

In other Maze Therapeutics news, CEO Jason V. Coloma sold 25,582 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $26.02, for a total value of $665,643.64. Following the sale, the chief executive officer owned 350,987 shares in the company, valued at approximately $9,132,681.74. This represents a 6.79% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 15,000 shares of the company’s stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $26.22, for a total transaction of $393,300.00. Following the completion of the transaction, the chief marketing officer owned 15,000 shares of the company’s stock, valued at approximately $393,300. This trade represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 74,502 shares of company stock worth $1,996,639. 5.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of MAZE. Janus Henderson Group PLC raised its position in shares of Maze Therapeutics by 318.0% in the fourth quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock worth $130,197,000 after acquiring an additional 2,390,713 shares during the period. Vanguard Group Inc. raised its position in shares of Maze Therapeutics by 218.1% in the third quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock worth $34,615,000 after acquiring an additional 915,342 shares during the period. Marshall Wace LLP increased its position in shares of Maze Therapeutics by 3,868.5% in the third quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock valued at $20,166,000 after buying an additional 758,104 shares in the last quarter. Caligan Partners LP purchased a new stake in shares of Maze Therapeutics in the fourth quarter valued at approximately $22,794,000. Finally, ArrowMark Colorado Holdings LLC purchased a new stake in shares of Maze Therapeutics in the third quarter valued at approximately $14,135,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.